Evolus (NASDAQ:EOLS) Reaches New 12-Month Low – Time to Sell?

Evolus, Inc. (NASDAQ:EOLS)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $10.16 and last traded at $10.21, with a volume of 505260 shares changing hands. The stock had previously closed at $10.74.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on EOLS shares. Barclays boosted their price target on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research note on Friday, September 13th. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Stock Performance

The stock has a 50 day simple moving average of $12.63 and a 200 day simple moving average of $13.77. The stock has a market cap of $646.51 million, a P/E ratio of -11.22 and a beta of 1.32. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in EOLS. Caligan Partners LP grew its position in Evolus by 1.2% during the 3rd quarter. Caligan Partners LP now owns 2,193,488 shares of the company’s stock worth $35,535,000 after acquiring an additional 25,698 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Evolus by 0.9% during the third quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company’s stock worth $19,616,000 after purchasing an additional 11,027 shares during the last quarter. Lord Abbett & CO. LLC increased its stake in shares of Evolus by 23.4% in the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after buying an additional 188,685 shares during the period. Assenagon Asset Management S.A. raised its holdings in Evolus by 0.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company’s stock valued at $15,480,000 after buying an additional 8,452 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in Evolus by 6.3% during the 3rd quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company’s stock worth $14,659,000 after buying an additional 53,605 shares during the period. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.